Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

Differential proteomics in the search for biomarkers of radiotherapy resistance (2011)
Journal Article
Scaife, L., Hodgkinson, V. C., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Differential proteomics in the search for biomarkers of radiotherapy resistance. Expert Review of Proteomics, 8(4), 535-552. https://doi.org/10.1586/EPR.11.32

The individualization of radiotherapy treatment would be beneficial for cancer patients; however, there are no predictive biomarkers of radiotherapy resistance in routine clinical use. This article describes the body of work in this field where compa... Read More about Differential proteomics in the search for biomarkers of radiotherapy resistance.

A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer (2011)
Journal Article
ELFadl, D., Hodgkinson, V. C., Long, E. D., Scaife, L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. The Breast : official journal of the European Society of Mastology, 20(4), 334-337. https://doi.org/10.1016/j.breast.2011.02.017

Breast conserving therapy is a currently accepted method for managing patients with early stage breast cancer. However, approximately 7% of patients may develop loco-regional tumour recurrence within 5 years. We previously reported that expression of... Read More about A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.